We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Liquid Biopsy Enables Early Diagnosis of Leptomeningeal Disease in Diffuse Midline Gliomas

By LabMedica International staff writers
Posted on 28 Jan 2025

Leptomeningeal disease (LMD) in diffuse midline gliomas (DMGs) can lead to debilitating symptoms such as intense pain, urinary incontinence, and tetraparesis, with limited treatment options available. More...

A new study has found that detecting H3F3A K27M-mutant droplets in cerebrospinal fluid (CSF) circulating tumor deoxyribonucleic acid (ctDNA) could serve as a biomarker for identifying LMD in DMGs.

In the study, researchers from Niigata University’s Brain Research Institute (Niigata, Japan) collected 25 CSF samples from 22 DMG patients. The team utilized droplet digital PCR, a highly sensitive PCR technique, to detect trace amounts of ctDNA from the CSF of these patients. They successfully diagnosed LMD in DMGs by identifying H3K27M-mutant droplets in the ctDNA from the CSF samples. The findings, published in Pediatric Blood & Cancer, show that in two patients, LMD was diagnosed earlier than through traditional methods like MRI and CSF cytology. In one case, early diagnosis of LMD followed by aggressive interventions, including surgery, radiation, and intrathecal chemotherapy, resulted in long-term survival. The study demonstrates that detecting H3F3A K27M-mutant droplets in CSF ctDNA is not only diagnostic for LMD but also more sensitive than traditional diagnostic techniques, such as CSF cytology and MR imaging.

“We found that detecting circulating tumor DNA in the cerebrospinal fluid of diffuse midline glioma patients was more difficult than other brain tumor patients such primary central nervous system lymphoma and glioblastoma,” said Dr. Manabu Natsumeda, who led the research team. “However, when we were able to detect mutant tumor DNA, often the tumor had already spread to the cerebrospinal fluid, causing leptomeningeal disease. We think that early diagnosis and treatment of leptomeningeal disease in diffuse midline gliomas can improve survival.”

Related Links:
Niigata University Brain Research Institute


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Urine Drug Test
Instant-view® Phencyclidine Urine Drug Test
New
cDNA Synthesis Kit
Ultimate cDNA Synthesis Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Ear wax could be a possible screening medium for Parkinson’s disease (Photo courtesy of 123RF)

Earwax Test Accurately Detects Parkinson’s by Identifying Odor Molecules

Current tests for Parkinson’s disease (PD) rely heavily on clinical scales and neuroimaging, which are often subjective, expensive, and ill-suited for routine screening. Since most treatments only slow... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: NGS can detect one tumor cell among a million healthy cells from a simple blood sample (Photo courtesy of Shutterstock)

New Tool Detects Breast Cancer Relapses Five Years in Advance

Relapse detection in patients with solid tumors—particularly hormone receptor-positive (HR+) breast cancer—remains a major clinical challenge, as many patients initially respond well to treatment but later... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.